New York, New York–(Newsfile Corp. – January 4, 2025) – Leading Securities Law Firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for possible violations of federal securities laws.
If you invested in BioAge, we recommend that you obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Why is BioAge being investigated?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company’s lead product candidate, azelaprag, is an orally available small molecule apelin receptor (APJ) agonist designed to improve weight loss.
During the relevant period, the company stated that azelaprag was well tolerated in 265 people in eight Phase 1 clinical trials and that following the company’s IPO the company was “well equipped to advance our clinical programs.”[.]”
Stocks drop as truth is revealed
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after hepatic transaminitis was observed in subjects receiving azelaprag. The company stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to the “emerging safety profile of the current doses tested.”[.]”
This news caused the company’s stock price to fall more than 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024. .
Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
What can you do?
If you invested in BioAge, you may have legal options and are advised to submit your information to the company.
All representation is done on a contingency fee basis, there is no cost to you. Shareholders are not responsible for legal costs or litigation expenses. The firm will seek court approval for potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named a Top 5 Plaintiff Law Firm by ISS SCAS in 2023 and its lawyers have been named Titans of the Plaintiff Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered more than $900 million in board value from Tesla (NASDAQ:), Inc. (pending court approval), as well as $420 million from Teva Pharmaceutical (NYSE:) Ind. .ltd.
For more information about BFA and its attorneys, visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Lawyer advertising. Past results do not guarantee future results.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235856